Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb;69(2):357-358.
doi: 10.4103/ijo.IJO_39_21.

Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns

Aman Kumar  1 , Divya Agarwal  1 , Atul Kumar  1
Affiliations
Comment

Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns

Aman Kumar et al. Indian J Ophthalmol. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None

Comment on

References

    1. Agarwal D, Kumar A. Managing intravitreal injections in adults in COVID-19 and post-COVID-19 era- Initial experiences. Indian J Ophthalmol. 2020;68:1216–8. - PMC - PubMed
    1. Griaud F, Winter A, Denefeld B, Lang M, Hensinger H, Straube F, et al. Identification of multiple serine to asparagine sequence variation sites in an intended copy product of LUCENTIS® by mass spectrometry. mAbs. 2017;9:1337–48. - PMC - PubMed
    1. Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Biosimilars for retinal diseases: An update. Am J Ophthalmol. 2020 S0002-9394(20)30651-6. doi: 10.1016/j.ajo.2020.11.017. - PubMed
    1. Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group Real-life clinical effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in retinal vein occlusion: A subgroup analysis of the pooled retrospective RE-ENACT Study. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd. 2019;241:24–31. - PMC - PubMed
    1. Sharma S, Khan M, Chaturvedi A RE-ENACT 2 Study Investigators Group. A multicenter, retrospective study (RE-ENACT 2) on RazumabTM (World's First Biosimilar Ranibizumab) in retinal vein occlusion. Ophthalmol Ther. 2020;9:625–39. - PMC - PubMed